The escalating global prevalence of antibiotic-resistant Helicobacter pylori strains has undermined conventional eradication therapies, heightening the burden of associated conditions such as gastritis, peptic ulcers and gastric malignancies. Emerging non-antibiotic alternatives, including natural and synthetic compounds, probiotics and vaccine candidates, offer potential solutions to combat these infections effectively. Natural and synthetic compounds provide promising anti-H. pylori effects, primarily through bacterial membrane disruption, urease inhibition, virulence gene suppression and biofilm prevention. in vitro and in vivo studies support the robust activity of natural agents, while synthetic counterparts demonstrate potent bactericidal and anti-adherence capabilities, though rigorous clinical validation is still required. Probiotic strains enhance eradication rates when combined with antibiotics, reduce treatment-related adverse effects, modulate gut microbiota and attenuate gastric inflammation and carcinogenesis. Vaccine development encompasses whole-cell, subunit and DNA platforms targeting key virulence factors, showing immunogenicity and protective efficacy in preclinical models, yet is limited by variable clinical translation and insufficient large-scale trials. Despite promising advancements, challenges persist, including inconsistent efficacy and a need for more rigorous human studies. Future efforts should emphasize combinatorial therapies, refined delivery systems, and thorough safety evaluations to integrate these strategies into clinical practice, fostering sustainable management of H. pylori in a post-antibiotic era.

This article examines the roles of nonhumans in the development, testing, and administration of COVID-19 vaccines. I show how specific groups of nonhumans, particularly primates, were strategically made visible and invisible to American publics, and how some groups were rendered more valuable than others. By studying the narratives of science that circulated during the pandemic, I argue that COVID-19, and the US response to it, illustrate a central facet of modern crisis, namely, that the current moment is marked by a growing awareness of human exposure to and vulnerability with nonhuman beings, coupled with an active and persistent denial of togetherness. To be a human subject in the twenty-first century involves acknowledging the interconnectedness that constitutes everyday life, while living in ways that openly reject this reality.

The effect of the narrator is understudied in the Narrative Policy Framework. We offer a systematic approach that details narrator definition, features (proximity to audience), and functions (audience trust). Informed by Construal Level Theory, we conducted an exploratory study (n = 2268) that assigned proximal to distal narrator features (“your friend,” “your doctor,” “the CDC,” and a control “someone”) and affixed narrators to visual messages about getting the COVID-19 vaccine. We investigated the extent to which proximity, trust, and congruence between narrator and narrative form predicts motivation to vaccinate. Narrator alone had no significant effect, but the proximal narrator paired with proximal characters in the policy message did have significant effects on motivation to vaccinate. Individual trust of distal narrators elicits affective responses, whereas individual trust of the proximal narrator is associated with motivation. These results suggest effects of narrator feature, characteristic, and function are dynamic and contextual.

African swine fever (ASF) is a highly contagious animal disease caused by African swine fever virus (ASFV). It is listed by the World Organization for Animal Health (WOAH) as an animal disease subject to statutory reporting. ASFV, a large, enveloped double-stranded DNA virus with high genomic complexity, exhibits a case fatality rate of up to 100%, posing a significant threat to the global pig industry and food safety. To date, the absence of a safe commercial ASFV vaccine primarily stems from challenges in identifying immunogenic viral antigens, insufficient characterization of ASFV pathogenesis, and limited understanding of the virus’s immune evasion mechanisms. Here, we review the pathogenic characteristics (morphological structure, clinical symptoms, and epidemiological characteristics), molecular biological characteristics, and infection mechanism of ASFV, as well as the immune response mechanism, vaccine research, and the latest information on ASFV in other areas. This review will be in favour of understanding the current state of knowledge of ASF and developing effective vaccines to control this disease.

Major shifts underway in US vaccine policies reflect widespread misinformation, notably including unproven claims of harms from vaccines. Vaccination misconceptions also include an array of falsities about the scope and extent of governmental powers and protections. Exposing these “legal myths” clarifies existing foundations of vaccine laws and policies, providing guidance on appropriate responses to quell vaccine hesitancy.

Invasive Escherichia coli disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for E. coli survival. To inform EXPEC9V development, a novel glycoconjugate vaccine targeting E. coli O-antigens that is no longer in active clinical development, this retrospective observational study describes O-serotype prevalence among E. coli isolates from IED patients. Eligible patients were identified from medical record databases (9 January 2018–8 November 2019) across 17 tertiary care hospitals in Europe, North America, and Asia. To estimate vaccine serotype coverage of EXPEC9V, E. coli isolates were O-serotyped using whole-genome sequencing and agglutination. Antimicrobial susceptibility testing was also performed. Nine hundred and two patients were enrolled, of whom 690 (76.5%) were aged ≥60 years. Common serotypes were O25, O2, O6, O1, O15, O75, O16, O4, and O18, with O25 being the most reported (17.3%). In patients aged ≥60 years, 422/637 E. coli isolates were EXPEC9V O-serotypes. EXPEC9V O-serotype prevalence did not substantially differ when stratified according to sex, presence of a positive blood culture, sepsis, fatality, or multidrug resistance. Consistent with previous studies, serotype O25 was most prevalent and associated with ~20% of cases. An EXPEC9V vaccine serotype coverage of 66.2% was observed for IED patients aged ≥60 years.

Tritrichomonas foetus causes bovine trichomonosis, a venereal disease that reduces productivity in naturally mated cattle. Its high prevalence in Northern Australian herds underscores the need for a locally made strain-specific vaccine. This study developed and tested a whole-cell killed T. foetus vaccine using the Queensland isolate TfOz5 (vaccine strain) and TfOz-N36 (Northern Territory isolate) as the challenge strain. The heat-inactivated vaccine, adjuvanted with Montanide ISA 61 VG, was administered subcutaneously in 2 doses (5 × 10⁷ cells/dose) at a 1-month interval to mature bulls (n = 6) (4–7 years old), while controls (n = 6) (4–8 years old) received adjuvant with PBS. Bulls were experimentally challenged intrapreputially with live cultures of T. foetus at 2- and 6-months post first vaccination. A therapeutic trial with T. foetus-positive, persistently infected mature bulls (n = 10) (4–7 years old) used the same vaccine regime without the subsequent T. foetus challenges. The vaccine was found to be safe, causing only mild local reactions. The vaccine challenge experiment demonstrated similar duration of T. foetus positivity, confirmed by quantitative polymerase chain reaction (qPCR), compared to controls (94 vs. 106 days, P = 0.73). In the therapeutic experiment, 2/10 treated bulls tested negative for T. foetus at the end of the trial, while the remaining eight remained positive. Vaccinated bulls in both experiments showed significantly elevated serum anti-T. foetus IgG antibody levels, confirming the vaccine’s immunogenicity. These findings demonstrate that the experimental vaccine is safe and capable of eliciting a specific immune response in mature bulls.

This article critically examines the inequities in the access to COVID-19 vaccine and the lessons for global health law. Despite the rapid development and approval of COVID-19 vaccines, the rollout exposed severe systemic failures rooted in preexisting economic distortions and market inefficiencies. The article argues that addressing vaccine inequity requires more than improved distribution and solidarity, but effective reinvention of the global vaccine supply chain through evidence-based and meaningful market-shaping measures. It calls for a transformative approach to global health governance, emphasising the need for a comprehensive, human rights-compliant policy framework to correct structural problems in international markets, moving beyond superficial exhortations to equity.

Multiple factors aligning in 2025 implicate challenges to vaccines as a primary public health intervention. Anti-vaccine proponents seek to recast immunization policies in promotion of perceived individual liberties. Recalibrating national vaccine approaches, however, runs counter to long-standing public health laws and policies grounded in a core truth: safe and effective vaccines save lives.

The article explores how the COVID-19 pandemic revived discussions on the importance of local pharmaceutical production for promoting health security and resilient health systems. It examines the World Health Organization's hub and spoke mRNA vaccine production model (mRNA hub), a global initiative that aims to establish sustainable, local mRNA manufacturing capabilities in low- and middle-income countries in response to the inequities in access to COVID-19 vaccines and the trade disruptions during the pandemic. Using the mRNA hub as case study, the paper discusses how the tectonic shift towards local production implicates supply and license agreements, and thus IPRs. The paper maps the intellectual property challenges that might impact the mRNA hub's sustainability and provides recommendations on how to enhance the initiative's chances of success and foster a more equitable pharmaceutical sector in the future.

Serogroup epidemiology of invasive meningococcal disease (IMD) is constantly evolving, varying by time and location. Surveillance reports have indicated a rise in meningococcal serogroup Y (MenY) in some regions in recent years. This systematic literature review explores the evolving epidemiology of MenY IMD globally based on review of recent articles and national surveillance reports published between 1 January 2010 and 25 March 2021. Generally, MenY incidence was low (<0.2/100,000) across all ages in most countries. The reported incidence was more frequent among infants, adolescents, and those aged ≥65 years. More than 10% of all IMD cases were MenY in some locations and time periods. Implementation of vaccination evolved over time as the rise in MenY IMD percentage occurred. Cases decreased in countries with quadrivalent vaccine programs (e.g., United Kingdom, the Netherlands, United States, and Australia), whereas the MenY burden increased and made up a large proportion of cases in areas without vaccine programs. Continuous monitoring of epidemiologic changes of IMD is essential to establish MenY burden and for implementation of prevention strategies.

Glycine-rich proteins (GRPs) are arbitrarily defined as those containing 20% or more glycine residues and constitute a superfamily divided into subfamilies based on their structure and/or function. GRPs have been identified in a diverse array of organisms and have been shown to possess a number of distinctive biological characteristics, including nucleic acid binding, adhesive glue-like properties, antimicrobial activity, involvement in the stress response and in the formation of cuticle components. In ticks, their expression has been described and studied mainly in the salivary glands, and their primary function is usually associated with cement formation and/or structure. Conversely, several GRPs are present in all tick developmental stages, and the expression of many GRP genes is modulated by physiological processes and immune challenges, such as feeding and pathogen infection. Considering that some tick GRPs appear to play essential roles in the tick life cycle, they have been evaluated as immune targets, with a focus on their potential application in vaccine development. This review highlights the roles that tick GRPs may perform beyond the formation and maintenance of the cement scaffold, including structural characterization, locations and functional relevance, hypothetical functions, and their potential use in anti-tick vaccine development.

Visceral leishmaniasis (VL) is a tropical disease that can be fatal if acute and untreated. Diagnosis is difficult, the treatment is toxic and prophylactic vaccines do not exist. Leishmania parasites express hundreds of proteins and several of them are relevant for the host's immune system. In this context, in the present study, 10 specific T-cell epitopes from 5 parasite proteins, which were identified by antibodies in VL patients’ sera, were selected and used to construct a gene codifying the new chimeric protein called rCHI. The rCHI vaccine was developed and thoroughly evaluated for its potential effectiveness against Leishmania infantum infection. We used monophosphoryl lipid A (MPLA) and polymeric micelles (Mic) as adjuvant and/or delivery system. The results demonstrated that both rCHI/MPLA and rCHI/Mic significantly stimulate an antileishmanial Th1-type cellular response, with higher production of IFN-γ, TNF-α, IL-12 and nitrite in vaccinated animals, and this response was sustained after challenge. In addition, these mice significantly reduced the parasitism in internal organs and increased the production of IgG2a isotype antibodies. In vivo and in vitro toxicity showed that rCHI is safe for the mammalians, and the recombinant protein also induced in vitro lymphoproliferative response and production of Th1-type cytokines by human cells, which were collected from healthy subjects and treated VL patients. These data suggest rCHI plus MPLA or micelles could be considered as a vaccine candidate against VL.

Since the beginning of mass vaccination campaign for COVID-19 in Italy (December 2020) and following the rapidly increasing vaccine administration, sex differences have been emphasized. Nevertheless, incomplete and frequently incoherent sex-disaggregated data for COVID-19 vaccinations are currently available, and vaccines clinical studies generally do not include sex-specific analyses for safety and efficacy. We looked at sex variations in the COVID-19 vaccine’s effectiveness against infection and severe disease outcomes. We conducted a nationwide retrospective cohort study on Italian population, linking information on COVID-19 vaccine administrations obtained through the Italian National Vaccination Registry, with the COVID-19 integrated surveillance system, held by the Istituto Superiore di Sanità. The results showed that, in all age groups, vaccine effectiveness (VE) was higher in the time-interval ≤120 days post-vaccination. In terms of the sex difference in vaccination effectiveness, men and women were protected against serious illness by vaccination in a comparable way, while men were protected against infection to a somewhat greater extent than women. To fully understand the mechanisms underlying the sex difference in vaccine response and its consequences for vaccine effectiveness and development, further research is required. The sex-related analysis of vaccine response may contribute to adjust vaccination strategies, improving overall public health programmes.

We conducted a retrospective cohort study in Ontario, Canada between December 1, 2020 and June 31, 2021 to compare the incidence of neurological events (hospitalization or emergency room visit) within six weeks of COVID-19 vaccination in Chinese, South Asian and Other ethnic groups. Compared to Others, the crude rates after the first dose for Bell’s palsy, ischemic stroke and intracerebral hemorrhage were lower in Chinese (34, 159 and 48 per 1,000,000 doses) and in South Asians (44, 148 and 32), but similar after adjusting for age, sex and vaccine type. Our findings should help encourage vaccination for all, irrespective of ethnicity.

Cystic echinococcosis control in South American countries requires a comprehensive integrative ‘One Health’ approach. While insular nations have seen successful in their elimination programmes, South American countries face persistent challenges in hostile environments, with Echinococcus granulosus s.l., posing a significant public health concern. Vaccination of intermediate hosts has demonstrated the efficacy of the EG95 vaccine in reducing transmission rates. For example, since 2009, Rio Negro Province in Argentina has added, with marked success, the EG95 vaccine to the control programme, supplementing dog deworming. The Aysen Region of Chile has also reported encouraging preliminary results in reducing cyst prevalence in vaccinated sheep after 3 years of vaccination. The challenges in aligning control strategies with socio-cultural factors, especially in indigenous communities, underlines the need for context-specific strategies. The Rio Negro programme demonstrated commendable compliance, underlining the importance of community engagement in achieving lasting success. The most promising strategies for effective echinococcosis control involved dog deworming and the routine vaccination of sheep and/or goats, underscoring the importance of sustained implementation until all grazing animals have been replaced. For lasting success, these interventions need to be combined with a robust surveillance system.